F070 The Morbilliform Eruption: Differentiation and Treatment of Viral, Low-risk Drug, Severe Cutaneous Adverse Reactions, and GVHD
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The morbilliform eruption is the most common cutaneous morphology encountered in the hospital setting. Despite its frequency, there is a dearth of literature and lectureships available to support evidenced-based guidelines especially for evaluation of the undifferentiated patient. This session will focus on the early and accurate diagnosis and differentiation of low-risk drug eruptions, severe cutaneous adverse reactions, viral eruptions, and GVHD in the adult patient.
LEARNING OBJECTIVES
Identify distinguishing characteristics that allow differentiation of morbilliform eruptions into high-risk and low-risk categories
Differentiate early severe cutaneous adverse reactions by morphologic differences, followed by confirmatory testing
Recognize laboratory testing and algorithms available to support the diagnosis of drug eruptions, viral reactions, and Graft-Versus-Host Disease.
SCHEDULE
7:30 PM
Introduction and Differentiation of High-Risk and Low-Risk Morbilliform Reactions
Sabrina Shearer, MD, FAAD
7:55 PM
Differentiating High-Risk Presentations and the Severe Cutaneous Adverse Reactions
Lauren Michelle Madigan, MD, FAAD
8:25 PM
Morbilliform Reactions in the Blood and Marrow Transplant Unit
Anna Cogen, MD, PhD, FAAD
8:45 PM
Morbilliform Reactions and Immunotherapy
Brittany L Dulmage, MD, FAAD
9:05 PM
Histopathology and Morbilliform Eruptions
Kristopher Fisher, MD, FAAD
9:15 PM
Using Data Science to Advance the Diagnosis and Management of Drug Eruptions
Vamsi Varra, MD, FAAD
SPEAKERS
Anna Cogen, MD, PhD, FAAD
Brittany L Dulmage, MD, FAAD
Kristopher Fisher, MD, FAAD
Benjamin Kaffenberger, MD, MS, FAAD
Lauren Michelle Madigan, MD, FAAD
Sabrina Shearer, MD, FAAD
Vamsi Varra, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Anna Cogen, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Brittany L Dulmage, MD, FAAD
Azitra, Inc – Investigator(Grants/Research Funding); Hoth Therapeutics – Data Safety Monitoring Board(Honoraria); Novocure – Consultant (1099 relationship)(Honoraria); Xencor – Consultant (1099 relationship)(Fees);
Kristopher Fisher, MD, FAAD
No financial relationships exist with ineligible companies.
Benjamin Kaffenberger, MD, MS, FAAD
Biogen – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding), Speaker(Fees); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria); National Psoriasis Foundation – Investigator(Grants/Research Funding);
Lauren Michelle Madigan, MD, FAAD
Blueprint Medicines – Advisory Board(Honoraria);
Sabrina Shearer, MD, FAAD
Bausch Health – Stockholder(Stock); IPG Photonics – Stockholder(Stock);
Vamsi Varra, MD, FAAD
No financial relationships exist with ineligible companies.